Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.

Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.

Item
http://www.wikidata.org/entity/Q46287219
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyAdiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosisLack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study.Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study.Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse heartsThe fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studySecond-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study.Role of Mitochondrial Oxidative Stress in Glucose Tolerance, Insulin Resistance, and Cardiac Diastolic Dysfunction.Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus.Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes.Heart failure with preserved ejection fraction: future directions in medical treatment.Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
P2860

Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.

Item
http://www.wikidata.org/entity/Q46287219
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@en
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@nl
type
label
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@en
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@nl
prefLabel
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@en
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Rosiglitazone, but not glimepi ...... s without overt heart disease.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921